BioSpace News Archive

Deals

Should Biogen Buy Alkermes?

After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.

February 28, 2018
·
3 min read
·
Karl Thiel
Drug Development

FDA Stuns Celgene With Refusal to File Letter for MS Treatment Ozanimod

The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod.

February 28, 2018
·
2 min read
·
Alex Keown
Job Trends

Inscripta Snags $55.5 Million in Funding, Looks to Expand Employment

Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.

February 28, 2018
·
2 min read
·
Alex Keown
Drug Development

Reata Pharmaceuticals Updates Data Release Dates for Ongoing Phase II Trials

Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.

February 28, 2018
·
2 min read
·
Alex Keown
Drug Development

PharmaCyte Presents Options for Phase II Pancreatic Cancer Trial

PharmaCyte Biotech recently discussed its options and plans for a Phase IIb clinical trial of its Cell-in-a-Box technology in pancreatic cancer.

February 28, 2018
·
3 min read
·
Mark Terry
Bio NC

Life Science Community Comes Together to Support Rare Disease Day

Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.

February 28, 2018
·
2 min read
·
Alex Keown
Career Advice

The Power of Body Language in the Job Interview

It’s not what you say sometimes but what you do. What are your non-verbal cues saying to a potential employer? Learn what to do to present yourself as the best candidate for the job, without ever saying a word.

February 28, 2018
·
6 min read
·
Briana Casali